Dayvigo tablets 2.5 mg for insomnia

General information on Japanese Dayvigo tablets 2.5 mg for insomnia     

Package details: 100 tablets

Manufacturer: Eisai Co., Ltd., Japan

Active ingredient: lemborexant (chemical formula C22H20F2N4O2)

Medical effect: Dayvigo tablets are effective for the treatment of insomnia.

Contraindications and precautions: do not use for pregnant and breastfeeding women.

If an allergic reaction occurs, stop using the medication and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Avoid drinking alcohol while taking this medicine. As the medicine may cause drowsiness and lack of concentration, avoid operating dangerous mechanisms or driving the car while taking this medicine.

Dosage and administration of Dayvigo tablets 2.5 mg from Japan for insomnia

For adults, take 2 tablets once a day, before bed. The dosage may be adjusted by the consulting doctor. The minimum dosage in 1 tablet a day before bed, the maximum dosage of 4 tablets a day should never be exceeded. 

How effective are Japanese Dayvigo tablets 2.5 mg for insomnia?

Dayvigo tablets contain lemborexant, a dual orexin receptor antagonist. It works by inhibiting orexin neurotransmission regulating sleep-wake rhythm. As a result, Dayvigo tablets provide the following effects:

• accelerate sleep onset,
• improve sleep maintenance,
• decrease the number of  middle of the night wakings,
• improve next morning postural stability and memory.

Who should use Dayvigo tablets 2.5 mg from Japan?

Dayvigo tablets are commended for the patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. These tablets do not produce physical dependence in those taking it for up to one year. Particularly, Dayvigo tablets are helpful for the elder patients as it improves postural stability and decreases the risk of falling (R. Rosenberg, P. Murphy et al. “Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial”. JAMA Network Open. 2019, December, 2(12) :e1918254. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2758000).